Nevro Reaffirms FY24 Revenue Guidance Of $435M-$445M (Est $441.038M), Sees Q2 Revenue Of $106M-$108M (Est $111.244M)

5/7/24 5:46:30 PM ET

Medical/Dental Instruments

Health Care

Get the next $NVRO alert in real time by email

Nevro is raising its adjusted EBITDA guidance for the full-year 2024 to a range of negative $5 million to positive $2 million from its previous guidance range of negative $14 million to negative $8 million.

For the second quarter of 2024, the company expects worldwide revenue to be in the range of approximately $106 million to $108 million and adjusted EBITDA to be in the range of negative $3.5 million to negative $2.5 million.

Get the next $NVRO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NVRO

Date	Price Target	Rating	Analyst
8/9/2024		Sell → Neutral	Citigroup
8/8/2024		Underperform → Peer Perform	Wolfe Research
8/7/2024		Mkt Outperform → Mkt Perform	JMP Securities
8/7/2024		Neutral → Underweight	JP Morgan
8/7/2024	$13.00 → $5.50	Equal Weight → Underweight	Wells Fargo
5/22/2024	$13.50 → $9.00	Neutral → Sell	Citigroup
2/22/2024		Outperform → Perform	Oppenheimer
1/12/2024	$23.00 → $20.00	Outperform → Sector Perform	RBC Capital Mkts

More analyst ratings

$NVRO
Financials

Live finance-specific insights

Nevro Reports Third-Quarter 2024 Financial Results
Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance REDWOOD CITY, Calif., Nov. 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results, reaffirmed its full-year 2024 revenue guidance and raised its full-year 2024 adjusted EBITDA guidance. "Our worldwide revenue and adjusted EBITDA came in better than we anticipated in the third quarter of 2024. In addition, our cash position reflects the benefits from our restructurings earlier this year as well as our focus on working capital ma
11/11/24 4:05:00 PM ET
$NVRO
Medical/Dental Instruments
Health Care
Nevro to Report Third-Quarter 2024 Financial Results and Host Earnings Conference Call on November 11, 2024
REDWOOD CITY, Calif., Oct. 10, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the third quarter of 2024 after the market closes on Monday, November 11, 2024. The company will also host a conference call beginning at 1:30 p.m. PST (4:30 p.m. EST) to discuss its financial results. The live webcast and replay of the conference call will be available in the Investor Relations section of the company's website at Events & Presentations. The webcast can be accessed 10 minutes prior to the conference call start time. For th
10/10/24 4:45:00 PM ET
$NVRO
Medical/Dental Instruments
Health Care
Nevro Reports Second-Quarter 2024 Financial Results
Initiates Process Aimed at Accelerating Growth, Diversifying Product Portfolio and Maximizing Stockholder Value Revises Full-Year 2024 Revenue Guidance to a Range of $400 million to $405 million and Adjusted EBITDA Guidance to a Range of $(20) Million to $(18) Million Provides Third-Quarter 2024 Guidance REDWOOD CITY, Calif., Aug. 6, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its second-quarter 2024 financial results, revised its full-year 2024 guidance, and issued third-quarter 2024 guidance. The company also announced that it is initiating a process
8/6/24 4:05:00 PM ET
$NVRO
Medical/Dental Instruments
Health Care

$NVRO
Press Releases

Fastest customizable press release news feed in the world

New Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral Approaches
Furthering Nevro's body of evidence as an innovation leader in pain management, data highlights the company's posterior integrated transfixation cage system REDWOOD CITY, Calif., Nov. 18, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of new data in Medical Devices: Evidence and Research, which demonstrate the superiority of the Nevro1™ SI Joint Fusion System ("Nevro1"), a posterior integrated transfixation cage system offering enhanced stability, minimized bone removal and increased fusion potential compared to a posterolateral cylindric
11/18/24 8:30:00 AM ET
$NVRO
Medical/Dental Instruments
Health Care
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
REDWOOD CITY, Calif., Nov. 15, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on November 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 37,726 shares of Nevro's common stock to 24 new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp. 2023 Inducement Award Plan and vests over a three-year period, subject to continued employment with Nevro through each vesting date. Each award was granted as a material inducem
11/15/24 8:30:00 AM ET
$NVRO
Medical/Dental Instruments
Health Care
Nevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion Globally
HFX iQ is the first and only spinal cord stimulation (SCS) system integrating high-frequency SCS landmark evidence with cloud data insights, leading the way for personalized, data-driven patient care* REDWOOD CITY, Calif., Nov. 12, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has received CE Mark Certification in Europe for its HFX iQ™ spinal cord stimulation (SCS) system. The CE marking allows Nevro to market HFX iQ in all countries that recognize this certification.
11/12/24 7:00:00 AM ET
$NVRO
Medical/Dental Instruments
Health Care

$NVRO
Leadership Updates

Live Leadership Updates

Nevro Enters Into Cooperation Agreement With Engaged Capital
Appoints Kirt P. Karros to Board of Directors REDWOOD CITY, Calif., Feb. 21, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has entered into a Cooperation Agreement with Engaged Capital, LLC ("Engaged Capital"), pursuant to which Kirt P. Karros has been appointed to Nevro's Board of Directors ("the Board") as well as the Audit Committee of the Board effective February 20, 2024. Mr. Karros is an accomplished finance executive with extensive experience in finance, including capital allocation and financial planning and analysis, as well as strategi
2/21/24 4:06:00 PM ET
$NVRO
Medical/Dental Instruments
Health Care
Nevro Appoints Jon R. Shear as Vice President, Corporate Development
REDWOOD CITY, Calif., April 19, 2021 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the appointment of Jon Shear to the newly created position of Vice President, Corporate Development, effective immediately. "Jon is uniquely qualified for this new role and brings extensive insight and understanding of the medical technologies industry to Nevro," said D. Keith Grossman, Chairman, CEO and President of Nevro. "As a member of our leadership team, he will be responsible for leading Nevro's strategic planning process, overseeing the business development function and
4/19/21 7:00:00 AM ET
$NVRO
Medical/Dental Instruments
Health Care
Nevro Appoints Julie D. Dewey as Vice President, Investor Relations and Corporate Communications
REDWOOD CITY, Calif., Nov. 30, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that Julie Dewey has joined the company as vice president, investor relations and corporate communications, effective immediately. "Julie has a tremendous depth of experience in all areas of investor relations and corporate communications, a deep knowledge of capital markets and has earned an outstanding reputation within the investment community," said Rod MacLeod, CFO of Nevro. "As a member of our leadership team, she will be instrumental in communicating the Nevro story a
11/30/20 7:00:00 AM ET
$NVRO
Medical/Dental Instruments
Health Care

Nevro Reaffirms FY24 Revenue Guidance Of $435M-$445M (Est $441.038M), Sees Q2 Revenue Of $106M-$108M (Est $111.244M)

Chat with this insight

Recent Analyst Ratings for $NVRO

$NVRO Financials

Live finance-specific insights

Nevro Reports Third-Quarter 2024 Financial Results

Nevro to Report Third-Quarter 2024 Financial Results and Host Earnings Conference Call on November 11, 2024

Nevro Reports Second-Quarter 2024 Financial Results

$NVRO Market Insights

Live Market Insights

Truist Securities Maintains Hold on Nevro, Lowers Price Target to $10

Beyond The Numbers: 6 Analysts Discuss Nevro Stock

Morgan Stanley Maintains Equal-Weight on Nevro, Lowers Price Target to $9

$NVRO SEC Filings

Nevro Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by Nevro Corp.

SEC Form S-8 filed by Nevro Corp.

$NVRO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Nevro upgraded by Citigroup

Nevro upgraded by Wolfe Research

Nevro downgraded by JMP Securities

$NVRO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

President & CEO Thornal Kevin R covered exercise/tax liability with 6,063 shares, decreasing direct ownership by 2% to 249,847 units (SEC Form 4)

SVP, Corp Dev and CLO Rashid Kashif covered exercise/tax liability with 479 shares, decreasing direct ownership by 0.30% to 161,352 units (SEC Form 4)

Director Weatherman Elizabeth H was granted 3,544 shares, increasing direct ownership by 5% to 80,846 units (SEC Form 4)

$NVRO Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Nevro Corp.

Amendment: SEC Form SC 13G/A filed by Nevro Corp.

Amendment: SEC Form SC 13G/A filed by Nevro Corp.

$NVRO Press Releases

Fastest customizable press release news feed in the world

New Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral Approaches

Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Nevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion Globally

$NVRO Leadership Updates

Live Leadership Updates

Nevro Enters Into Cooperation Agreement With Engaged Capital

Nevro Appoints Jon R. Shear as Vice President, Corporate Development

Nevro Appoints Julie D. Dewey as Vice President, Investor Relations and Corporate Communications

Recent Analyst Ratings for
$NVRO

$NVRO
Financials

$NVRO
Market Insights

$NVRO
SEC Filings

$NVRO
Analyst Ratings

$NVRO
Insider Trading

$NVRO
Large Ownership Changes

$NVRO
Press Releases

$NVRO
Leadership Updates